SCNLF (Scancell Holdings) EBIT: $-8.50 Mil (TTM As of Oct. 2025)

What is Scancell Holdings EBIT?

Scancell Holdings SCNLF 20 EBIT is $-8.50 Mil as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Scancell Holdings's earnings before interest and taxes (EBIT) for the six months ended in Oct. 2025 was $-7.79 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Oct. 2025 was $-8.50 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Scancell Holdings's annualized ROC % for the quarter that ended in Oct. 2025 was -59.34%. Scancell Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Oct. 2025 was -1,760.32%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Scancell Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Oct. 2025 was -3.25%.

Scancell Holdings (OTCPK:SCNLF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Scancell Holdings's annualized ROC % for the quarter that ended in Oct. 2025 is calculated as:

	ROC % (Q: Oct. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Apr. 2025 )	+	Invested Capital (Q: Oct. 2025 ))	/ count )
=	-23.744 * ( 1 - 15.66% )	/	( (37.172	+	30.324)	/ 2 )
=	-20.0256896	/	33.748
=	-59.34 %

where

	Invested Capital		(Q: Apr. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	30.342	-	1.288	-	( 22.2	-	max(0, 35.219	-	27.101	+	22.2	))
=	37.172

	Invested Capital		(Q: Oct. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	20.53	-	4.2	-	( 11.447	-	max(0, 31.708	-	17.714	+	11.447	))
=	30.324

Note: The Operating Income data used here is two times the semi-annual (Oct. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Scancell Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Oct. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Oct. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Apr. 2025		Q: Oct. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-15.57	/	( ( (1.113 + max(-9.104, 0))	+	(0.656 + max(-3.836, 0)) )	/	2 )
=	-15.57	/	( ( 1.113	+	0.656 )	/	2 )
=	-15.57	/	0.8845
=	-1,760.32 %

where Working Capital is:

	Working Capital		(Q: Apr. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	4.901)	-	(1.288	+	0	+	12.717)
=	-9.104

	Working Capital		(Q: Oct. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.712	+	0	+	5.555)	-	(4.2	+	0	+	5.903)
=	-3.836

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Oct. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Scancell Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Oct. 2025 )
	=	-8.497	/	261.841
	=	-3.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scancell Holdings EBIT Related Terms

Scancell Holdings EBIT Historical Data

* Premium members only.

The historical data trend for Scancell Holdings's EBIT can be seen below:

Scancell Holdings EBIT Chart

Scancell Holdings Annual Data

Trend

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

Apr25

EBIT

Get a 7-Day Free Trial

-20.99

-5.82

-16.30

-10.05

-17.85

Scancell Holdings Semi-Annual Data
	Apr16	Oct16	Apr17	Oct17	Apr18	Oct18	Apr19	Oct19	Apr20	Oct20	Apr21	Oct21	Apr22	Oct22	Apr23	Oct23	Apr24	Oct24	Apr25	Oct25
EBIT	Get a 7-Day Free Trial															-3.77	-6.17	-17.01	-0.71	-7.79

SCNLF vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Scancell Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scancell Holdings EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's EV-to-EBIT falls into.

Save Embed

20GF Score

Scancell Holdings PLC SCNLF

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Scancell Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Oct. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-8.50 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-8.50 Mil mean?

Scancell Holdings (SCNLF) has a EBIT of $-8.50 Mil as of Oct. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Scancell Holdings.

Is Scancell Holdings' EBIT too high?

Scancell Holdings' current EBIT is $-8.50 Mil. Overall, Scancell Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.

How does Scancell Holdings' EBIT compare to VRTX and REGN?

Scancell Holdings' EBIT of $-8.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Scancell Holdings. Scancell Holdings's current EBIT is $-8.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Scancell Holdings stock overvalued right now?

Scancell Holdings (SCNLF) has a current EBIT of $-8.50 Mil. The current EBIT is $-8.50 Mil. Scancell Holdings' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current EBIT is $-8.50 Mil as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scancell Holdings Business Description

Industry Healthcare Biotechnology

Comparable Companies LSE:IBT LSE:PRTC LSE:AVCT LSE:FARN LSE:BVXP LSE:4BB LSE:HEMO LSE:COIL LSE:POLB LSE:SAR VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges SCLP:UK SCP:Germany

Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD

Website https://www.scancell.co.uk

Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.

20GF Score

Get the complete analysis for SCNLF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28

Price

View SCNLF Analysis

See EBIT data for all stocks →